Semaglutide's renal hemodynamic and functional effects in type 2 diabetes with nephropathy to be explored in crossover study

Patients with Type 2 Diabetes Mellitus (T2DM) frequently develop diabetic nephropathy, a leading cause of chronic kidney disease (CKD) and end-stage renal disease. Current standard-of-care often involves managing blood glucose and blood pressure, but specific renoprotective therapies that directly address renal hemodynamics and oxygenation are still needed. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide have demonstrated significant cardiovascular and renal benefits in T2DM, as evidenced by large outcome trials. However, the precise mechanisms by which GLP-1RAs exert these renoprotective effects, particularly on specific renal arterial blood flow, regional perfusion, oxygenation, and the renin-angiotensin-aldosterone system (RAAS), are not fully elucidated. This study aims to fill that mechanistic gap.

This research is a double-blinded, placebo-controlled, randomized, crossover study designed to evaluate the effects of semaglutide on renal hemodynamics and function. The study will enroll patients diagnosed with type 2 diabetes mellitus (T2DM) and moderate chronic kidney disease (CKD). Participants will receive either semaglutide or placebo in a crossover design, ensuring each patient serves as their own control. The primary endpoints include changes in renal arterial blood flow, regional renal perfusion, and oxygenation. Secondary endpoints will assess the activity of the renin-angiotensin-aldosterone system (RAAS), the glomerular filtration rate (GFR), sodium excretion in urine, blood pressure, and heart rate. Specific doses, routes, and durations are not detailed in this protocol abstract, but the design aims to provide a comprehensive physiological assessment.

This publication describes the protocol for a double-blinded, placebo-controlled, randomized, crossover study investigating semaglutide's effects on renal hemodynamics and function in patients with type 2 diabetes and moderate chronic kidney disease. As such, specific findings and numerical results are not yet available from this publication. The study is designed to determine how semaglutide influences key physiological parameters such as renal arterial blood flow, regional renal perfusion, and oxygenation. It also aims to quantify changes in the activity of the renin-angiotensin-aldosterone system (RAAS), the glomerular filtration rate (GFR), and urinary sodium excretion. Blood pressure and heart rate will also be monitored. The results of this study are anticipated to provide mechanistic insights into the renoprotective actions of GLP-1RAs.